Revolution Medicines (RVMD) EBIAT: 2019-2025
Historic EBIAT for Revolution Medicines (RVMD) over the last 7 years, with Sep 2025 value amounting to -$305.2 million.
- Revolution Medicines' EBIAT fell 95.28% to -$305.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$961.0 million, marking a year-over-year decrease of 69.47%. This contributed to the annual value of -$600.1 million for FY2024, which is 37.52% down from last year.
- Per Revolution Medicines' latest filing, its EBIAT stood at -$305.2 million for Q3 2025, which was down 23.17% from -$247.8 million recorded in Q2 2025.
- Over the past 5 years, Revolution Medicines' EBIAT peaked at -$37.2 million during Q1 2021, and registered a low of -$305.2 million during Q3 2025.
- Moreover, its 3-year median value for EBIAT was -$156.3 million (2024), whereas its average is -$163.9 million.
- Data for Revolution Medicines' EBIAT shows a maximum YoY crashed of 185.87% (in 2023) over the last 5 years.
- Over the past 5 years, Revolution Medicines' EBIAT (Quarterly) stood at -$52.7 million in 2021, then declined by 7.27% to -$56.5 million in 2022, then tumbled by 185.87% to -$161.5 million in 2023, then fell by 20.45% to -$194.6 million in 2024, then slumped by 95.28% to -$305.2 million in 2025.
- Its EBIAT was -$305.2 million in Q3 2025, compared to -$247.8 million in Q2 2025 and -$213.4 million in Q1 2025.